CIS1 Antibody

What is CIS1 and what is its functional significance in cell signaling?

CIS1 (Cytokine-inducible SH2-containing protein 1) is a regulatory protein involved in cytokine signaling pathways. It functions as a critical negative regulator in multiple cellular processes and has been implicated in various cancer pathways. The human CIS-1 protein (Accession # Q9NSE2) spans from Leu11 to Leu258 and is typically detected at molecular weights between 35-42 kDa, depending on the experimental system and potential post-translational modifications . CIS1 has emerged as a significant research target due to its involvement in cancer pathways, particularly in relation to anticancer drug resistance mechanisms and autophagy regulation in gastric cancer cells and non-small cell lung cancer .

What are the structural and biochemical characteristics of commercially available CIS1 antibodies?

Most research-grade CIS1 antibodies are developed using E. coli-derived recombinant human CIS-1 as the immunogen. For example, the Goat Anti-Human CIS-1 Antigen Affinity-purified Polyclonal Antibody (AF3194) recognizes specific epitopes on the CIS-1 protein . These antibodies typically demonstrate high specificity, recognizing CIS-1 at approximately 35-40 kDa in Western blots of human cell lysates and at 37 and 42 kDa in Simple Western assays . Immunocytochemistry experiments reveal that CIS-1 is predominantly localized to the cytoplasm, as demonstrated in studies with HDLM-2 human Hodgkin's lymphoma cell lines .

How does CIS1 relate to cancer pathways and drug resistance mechanisms?

CIS1 has been identified as a component of the CAGE–MiR-181b-5p–S1PR1 axis that regulates anticancer drug resistance and autophagy in gastric cancer cells . Additionally, research has shown that CIS1/CAGE may mediate osimertinib resistance in non-small cell lung cancer cells and could serve as a predictor of poor prognosis in patients with pulmonary adenocarcinoma . These findings highlight the potential of CIS1 as a biomarker and therapeutic target in cancer research, particularly in the context of overcoming drug resistance in cancer treatment.

What are the validated applications for CIS1 antibodies in research?

CIS1 antibodies have been validated for several experimental applications:

These applications can be further optimized depending on the specific experimental system and research questions being addressed .

What protocol modifications are recommended for optimal Western blot detection of CIS1?

For optimal Western blot detection of CIS1, researchers should consider the following protocol adjustments:

• Use PVDF membrane for protein transfer, as this has been validated with CIS1 antibodies

• Conduct experiments under reducing conditions using Immunoblot Buffer Group 8

• Apply antibody at a concentration of 1 μg/mL for primary detection

• Expect to detect CIS1 at approximately 35-40 kDa, though multiple bands may indicate different isoforms or post-translational modifications

• Include appropriate positive controls such as lysates from Nalm-6 human Pre-B acute lymphocytic leukemia cell line, which has demonstrated reliable CIS1 expression

How should immunofluorescence protocols be optimized for CIS1 detection in different cell types?

For immunofluorescence detection of CIS1:

• Use immersion fixation for cell preparation, which has been successfully employed with HDLM-2 human Hodgkin's lymphoma cell line

• Apply CIS1 antibody at a concentration of 15 μg/mL and incubate for 3 hours at room temperature

• Utilize fluorochrome-conjugated secondary antibodies such as NorthernLights 557-conjugated Anti-Goat IgG

• Counterstain nuclei with DAPI to provide cellular context

• Look for specific cytoplasmic localization pattern, which is the expected cellular distribution of CIS1

• For non-adherent cells, employ specialized protocols such as "Fluorescent ICC Staining of Non-adherent Cells" which has been developed specifically for this purpose

How can I design comprehensive experiments to investigate CIS1's role in drug resistance?

To effectively study CIS1's role in drug resistance mechanisms:

• Select appropriate cell models based on documented CIS1 expression (e.g., gastric cancer or non-small cell lung cancer cell lines that have shown CIS1 involvement)

• Establish drug-resistant cell lines through gradual exposure to increasing concentrations of relevant anticancer drugs

• Compare CIS1 expression levels between drug-sensitive and drug-resistant cells using quantitative Western blot and qPCR

• Implement knockdown and overexpression approaches to directly manipulate CIS1 levels and assess functional consequences

• Investigate the relationship between CIS1 and the CAGE–MiR-181b-5p–S1PR1 axis, as this pathway has been implicated in drug resistance mechanisms

• Include autophagy markers in your analysis, as CIS1 has been connected to autophagy regulation in cancer cells

• Validate findings using patient-derived samples where possible to confirm clinical relevance

What are the critical controls needed for CIS1 antibody experiments?

Robust experimental design requires the following controls when working with CIS1 antibodies:

• Positive controls: Include cells known to express CIS1 such as Nalm-6, HDLM-2, or NK lymphoma cell lines

• Negative controls: Utilize cells with low/no CIS1 expression or CIS1 knockdown cells

• Technical controls:

  • Secondary antibody-only control to assess background staining

  • Isotype control to evaluate non-specific binding

  • Loading controls for Western blot (e.g., housekeeping proteins)

• Validation controls: When performing functional studies, include both gain-of-function (overexpression) and loss-of-function (knockdown) approaches to confirm specificity of observed effects

How can I address batch variation and reproducibility issues with CIS1 antibodies?

To minimize variability and ensure reproducibility:

• Validate each new antibody lot against a reference standard or previously characterized samples

• Standardize experimental conditions including cell culture parameters, lysis protocols, and antibody dilutions

• Implement a quality control system with positive control samples of known CIS1 expression levels

• Document precise experimental conditions, including buffer compositions, incubation times, and detection systems

• Consider using recombinant CIS1 as a calibration standard when performing quantitative analyses

• Use orthogonal methods (e.g., mass spectrometry) to verify key findings obtained with antibody-based techniques

• Conduct replicate experiments across different days and with different antibody lots to assess reproducibility

How should I interpret multiple bands in Western blots when detecting CIS1?

The detection of multiple bands in CIS1 Western blots requires careful interpretation:

• CIS1 has been detected at approximately 35-40 kDa in standard Western blots and at 37 and 42 kDa in Simple Western assays , suggesting potential isoforms or post-translational modifications

• To characterize these variations:

  • Compare with recombinant CIS1 standards of known molecular weight

  • Consider phosphatase treatment to identify phosphorylated forms

  • Analyze samples under both reducing and non-reducing conditions

  • Employ 2D gel electrophoresis to separate variants based on both isoelectric point and molecular weight

• Document the specific conditions of your experimental system, as these molecular weight differences may have functional significance

• When publishing results, clearly report all observed bands and provide rationale for which band(s) represent CIS1 in your system

What approaches should be used to quantify CIS1 expression in different experimental systems?

For quantitative analysis of CIS1 expression:

• Western blot densitometry:

  • Normalize band intensities to appropriate loading controls

  • Use standard curves with recombinant protein when possible

  • Ensure signal is within linear detection range

  • Analyze at least three biological replicates

• Immunofluorescence quantification:

  • Establish consistent image acquisition parameters

  • Measure mean fluorescence intensity across multiple fields

  • Analyze at least 100-200 cells per condition

  • Apply appropriate background subtraction methods

  • Consider single-cell analysis to assess population heterogeneity

• Statistical approaches:

  • Apply appropriate statistical tests based on data distribution

  • Report both biological and technical variability

  • Consider power analysis to determine adequate sample sizes

How can I integrate CIS1 expression data with functional studies on drug resistance?

To meaningfully connect CIS1 expression with functional outcomes:

• Establish clear dose-response relationships between CIS1 expression levels and drug sensitivity profiles

• Perform time-course experiments to determine whether CIS1 expression changes precede or follow the development of drug resistance

• Use correlation analysis to assess relationships between CIS1 expression and other markers of drug resistance

• Apply multivariate analysis to identify key variables that influence the relationship between CIS1 and drug response

• Consider developing predictive models that incorporate CIS1 expression along with other biomarkers to forecast drug resistance

• Validate findings across multiple cell lines and, ideally, patient-derived samples to establish broader relevance

How can CIS1 antibodies be utilized in bispecific antibody development for cancer therapeutics?

Bispecific antibody development involving CIS1 could follow these approaches:

• Design considerations:

  • Structure-based design principles can be applied to engineer bispecific antibodies targeting CIS1 along with another relevant cancer marker

  • The format selection (e.g., IgG-like vs. fragment-based) should be guided by the intended mechanism of action and target accessibility

• Engineering strategies:

  • Various platform technologies exist for creating bispecific antibodies, including chain-steering mutations and glycoengineering

  • Fc engineering can be employed to either enhance or reduce effector functions depending on the therapeutic goal

• Functional validation:

  • Assays measuring cross-interaction and self-association should be used to evaluate developability

  • High-throughput assays such as AC-SINS or CSI-BLI can predict antibody stability and production characteristics

What advanced techniques can be employed to study the dynamic interactions of CIS1 in cellular signaling networks?

Advanced techniques for studying CIS1 dynamics include:

• Proximity-based methods:

  • Proximity ligation assays to detect protein-protein interactions in situ

  • FRET-based approaches to monitor real-time interactions

  • BioID or APEX2 proximity labeling to identify the CIS1 interactome

• Live-cell imaging techniques:

  • Fluorescently-tagged CIS1 to track localization dynamics

  • Photoactivatable or photoconvertible fusion proteins to study protein turnover

  • CRISPR-based endogenous tagging for physiologically relevant expression levels

• Multi-omics integration:

  • Combine CIS1 antibody-based studies with transcriptomics, proteomics, and phosphoproteomics

  • Apply network analysis tools to construct comprehensive signaling models

  • Use machine learning approaches to identify patterns and predict outcomes

How can CIS1 antibodies be modified to enhance their research applications?

Advanced modifications of CIS1 antibodies may include:

• Conjugation strategies:

  • Site-specific conjugation to fluorophores, enzymes, or nanoparticles to enable diverse detection methods

  • Development of antibody-drug conjugates for targeted therapy research

  • Creation of bifunctional reagents for pull-down or crosslinking applications

• Affinity engineering:

  • Modification of CDR regions to enhance binding specificity and reduce background

  • Use of canonical structure knowledge to predict and modify binding characteristics

  • Humanization of antibodies for improved performance in human cell systems

• Format diversification:

  • Generation of single-chain variable fragments (scFvs) for applications requiring smaller size

  • Development of intrabodies for targeted intracellular applications

  • Creation of multivalent formats to enhance avidity for weakly expressed targets